PURCHASE, NY, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, today announced that it issued inducement awards to three new employees.
Effective December 1, 2023 and December 5, 2023, in connection with commencing employment, three new non-executive employees of Teladoc Health were granted options to purchase an aggregate of 106,255 shares of Teladoc Health’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price per share of $18.97 and $18.51, respectively, and awards of restricted stock units covering an aggregate of 86,154 shares of Common Stock. The stock options vest, based on continued service to Teladoc Health, as to twenty-five percent of the underlying shares on December 1, 2024, with the remainder of the options vesting monthly over three years thereafter. The restricted stock units vest, based on continued service to Teladoc Health, as to one-third of the underlying shares on December 1, 2024, with the remainder vesting quarterly over two years thereafter. The awards were approved by the Compensation Committee of the Board of Directors of Teladoc Health and were granted under the Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan as employment inducement awards pursuant to New York Stock Exchange Rule 303A.08.
About Teladoc Health
Teladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in whole-person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health journey. Teladoc Health leverages more than two decades of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com
Media:
Chris Stenrud
860-491-8821
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$6.90 |
| Daily Change: | -0.24 -3.36 |
| Daily Volume: | 4,380,307 |
| Market Cap: | US$1.190B |
March 12, 2025 March 11, 2025 March 04, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
